1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. MarketScreener Strategies
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-08-12 am EDT
770.00 DKK   -2.67%
08/12NOVO NORDISK A/S : Ex-dividend day for interim dividend
FA
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associated persons
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : The technical configuration is positive

06/30/2022 | 02:38am EDT
long trade
Live
Entry price : 781DKK | Target : 900DKK | Stop-loss : 730DKK | Potential : 15.24%
The underlying tendency is to the upside for shares in Novo Nordisk A/S and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Investors have an opportunity to buy the stock and target the DKK 900.
Novo Nordisk A/S : Novo Nordisk A/S : The technical configuration is positive
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses
  • With an expected P/E ratio at 32.81 and 26.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart
Subsector Other Pharmaceuticals
1st jan.Capitalization (M$)Investor Rating
NOVO NORDISK A/S4.76%240 550
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
MERCK & CO., INC.18.76%230 579
ASTRAZENECA PLC23.44%201 219
NOVARTIS AG-0.22%185 374
BRISTOL-MYERS SQUIBB COMPAN..21.20%161 361
AMGEN INC.10.41%132 871
More Results

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2022 171 B 23 606 M 23 606 M
Net income 2022 54 457 M 7 506 M 7 506 M
Net cash 2022 2 051 M 283 M 283 M
P/E ratio 2022 31,5x
Yield 2022 1,54%
Capitalization 1 745 B 241 B 241 B
EV / Sales 2022 10,2x
EV / Sales 2023 8,89x
Nbr of Employees 50 816
Free-Float 69,6%
Upcoming event on NOVO NORDISK A/S
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 770,00 DKK
Average target price 827,04 DKK
Spread / Average Target 7,41%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer